Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SYDNEY, Nov. 4, 2021 /PRNewswire-AsiaNet/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed ...
Authors: LATEST ASIANET NEWS RELEASES